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The SAG2 vaccine (RABIGEN® SAG2) is a modified live attenuated rabies virus vaccine, selected from the SAD Bern
strain in a two-step process of amino acid mutation using neutralizing monoclonal antibodies. The strain is genetically
stable and does not spread in vivo or induce a persistent infection. Its absence of residual pathogenicity was extensively
demonstrated in multiple target and non target species (such as wild carnivores and rodent species), including
non-human primates. The efficacy of SAG2 baits was demonstrated according to the EU requirements for the red
fox and raccoon dog. The use of safe and potent rabies vaccines such as SAG2 largely contributed to the elimination of
rabies in Estonia, France, Italy and Switzerland. Importantly, these countries were declared free of rabies after few years of
oral vaccination campaigns with SAG2 baits distributed with an appropriate strategy. The excellent tolerance of the SAG2
vaccine has been confirmed in the field since its first use in 1993. No safety issues have been reported, and in particular
no vaccine-induced rabies cases were diagnosed, after the distribution of more than 20 million SAG2 baits in Europe.Table of contents
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Rabies is an acute progressive fatal viral encephalitis,
caused by negative stranded RNA viruses in the Genus
Lyssavirus (Family Rhabdoviridae, Order Mononegavirales).
The disease is widely distributed on all continents except
Antarctica [1].
In the early 1960s, wildlife emerged as the main reser-
voir for rabies virus in many developed countries. During
the last decade, more than 90% of rabies cases occurring
in Europe were reported in wildlife [2]. Until the 1970s,is an Open Access article distributed under the terms of the Creative
ns.org/licenses/by/4.0), which permits unrestricted use, distribution, and
ork is properly credited. The Creative Commons Public Domain
cdomain/zero/1.0/) applies to the data made available in this article,
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reduction of rabies reservoir species by trapping and
hunting foxes or other carnivores, gassing fox dens or
distributing poisoned baits [3-6]. These measures
proved ineffective in reducing rabies prevalence. An
alternative strategy was considered, consisting of wildlife
immunization using oral vaccine baits [7]. For the first
time, the feasibility of vaccinating wildlife was demon-
strated in Switzerland during 1978 using modified live
rabies virus vaccines [8].
Most modified-live rabies virus vaccines used for oral
vaccination (OV) originated from the attenuated Evelyn
Rokitnicki Abelseth (ERA) virus strain, which was de-
rived from the original Street-Alabama-Dufferin (SAD)
rabies virus strain. The parental SAD strain was isolated
from the salivary glands of a rabid dog in the USA during
1935, which was passaged in mice, chick embryos, and
various cell lines and was re-named ERA [9]. The SAD
Bern strain is a cell-adapted derivative of the ERA strain,
and was used for the first trials of OV in Switzerland [10].
The SAD B19 and SAD 5/88 strains were derived from
the SAD Bern by selection on cloned BHK21 cells [11].
However, SAD Bern, SAD B19 and SAD P5/88 retained
a non negligible residual pathogenicity in rodents and in
wild and domestic carnivores, even by the oral route
[12-15]. Thus, using those strains in the field, there is a
potential risk for contamination of target and non-target
animal species during OV campaigns (for review, see the
recent paper of Hostnik et al. [16]). The SAG2 strain
(SAD Avirulent Gif), is a modified live virus strain selected
from SAD Bern during 1990 by two successive mutations
[17]. All the three strains (SAD B19, SAD Bern and
SAG2) are currently used for OV of wildlife in Europe
[18]. A recombinant vaccinia virus and a recombinant
human adenovirus vector, both expressing the rabies
glycoprotein of the ERA strain (V-RG and ONRAB, re-
spectively) are also available. Those vaccines are mainly
in use in the USA [19] and Canada [20].
Given its long history of safe and effective use in the
field, this paper reviews the process development and
main biological properties of the SAG2 strain, together
with the experience of rabies control programmes under-
taken with this vaccine in different European countries.
2. Main characteristics of the SAG2 vaccine
2.1 Development of the SAG2 strain Figure 1
The World Health Organization (WHO) organized
several meetings with rabies experts to define safety and
efficacy requirements for OV use in wildlife and in dogs
[3-6]. One approach, using hybridoma technology, was
used to ensure the safety of the rabies virus vaccine
strain, based upon the concept of selective antigenic
variants [21]. The SAD Bern strain was cultivated in the
presence of monoclonal antibodies binding specificallyto one of the two major antigenic sites (antigenic site
III) of the rabies virus glycoprotein, which is involved in
virus pathogenicity. Under the selective pressure of
these monoclonal antibodies, only variants of SAD Bern
bearing an amino-acid substitution at the critical position
333 of the rabies virus glycoprotein escaped neutralisation
in culture [22].
An avirulent mutant, SAG1 (for SAD Avirulent Gif ),
in which arginine at position 333 was substituted by
serine, was isolated from SAD Bern with monoclonal
antibody 50 AD1 [14,23,24]. This mutant was found to
be avirulent in all animal species tested and in adult mice,
regardless of the dose and route of inoculation [12,14].
The SAG1 virus was shown to be as immunogenic as the
parental strain of SAD Bern. The substitution of arginine
at position 333 improved considerably the safety of the
vaccine strain without impairing its efficacy [23,24]. Since
the frequency of spontaneous mutations in RNA viruses
has been estimated to be about 10-4 [25], there was a
theoretical, albeit limited, risk of reversion to a different
phenotype which might possibly affect pathogenicity
(equivalent to SAD Bern). To improve the genetic sta-
bility of the vaccine and upon request of the regulatory
authorities, a double avirulent vaccine was developed
with the Centre National de la Recherche Scientifique
(CNRS, France). The SAG2 strain was constructed from
SAD Bern in a two-step selection procedure using neutral-
izing monoclonal antibodies [17]. First, a mutant strain
(SK) was selected from SAD Bern, where the arginine at
position 333 was replaced by lysine. The SK strain was
resistant to monoclonal antibody 50 AD1 and partially
resistant to monoclonal antibody 50 AC1. The SK strain
was avirulent when injected intramuscularly in adult mice
and had an extremely low pathogenicity by the intrace-
rebral route [17]. A mutant resistant to neutralisation
by monoclonal antibody 50 AC1 was selected from SK,
where the lysine at position 333 was replaced by a glutamic
acid. This mutant, called SAG2, was non-pathogenic in
adult mice, even by the intracerebral route [17]. Thus,
SAG2 can be considered as a double avirulent mutant,
since the codon GAA, which codes for glutamic acid,
differs from the codon AGA from SAD Bern (coding for
arginine) by two nucleotides [17,22-24].
2.2 Genetic stability
The laboratory mouse is one of most susceptible species
to rabies virus, and the parental strain SAD Bern is
highly pathogenic for adult mice by the intracerebral
route [14]. Therefore, studies on reversion to virulence
were conducted in mice. The model selected for serial
passages was the suckling mouse. Suckling mice do not
possess a sufficiently mature immune system to control
rabies virus infection in the central nervous system and
they are, for other reasons, particularly receptive to rabies
Figure 1 Construction of the SAG2 strain. ERA = Evelyn Rokitnicki Abelseth, Mab =monoclonal antibody. The parental SAD strain was isolated
from the salivary glands of a rabid dog in the USA during 1935, which was passaged in mice, chick embryos, and various cell lines and was
re-named ERA (Evelyn Rokitnicki Abelseth). The SAD Bern strain is a cell-adapted derivative of the ERA strain. The SAD Bern strain was cultivated
in the presence of monoclonal antibodies binding specifically to one of the two major antigenic sites (antigenic site III) of the rabies virus
glycoprotein, involved in virus pathogenicity. Under the selective pressure of these monoclonal antibodies, only variants of SAD Bern bearing
an amino-acid substitution at the critical position 333 of the rabies virus glycoprotein escaped neutralisation in culture. An avirulent mutant,
SAG1 (for SAD Avirulent Gif), in which arginine at position 333 was substituted by serine, was isolated from SAD Bern with monoclonal antibody
(Mab) 50 AD1. The SAG2 strain was constructed from SAD Bern in a two-step selection procedure using neutralizing monoclonal antibodies.
First, a mutant strain (SK) was selected from SAD Bern, where the arginine at position 333 was replaced by lysine. SAG2, a non pathogenic
mutant resistant to neutralisation by monoclonal antibody 50 AC1 was selected from SK, where the lysine at position 333 was replaced by a
glutamic acid. Thus, SAG2 can be considered as a double avirulent mutant, since the codon GAA, which codes for glutamic acid, differs from
the codon AGA from SAD Bern (coding for arginine) by two nucleotides.
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rebral passages were conducted in suckling mice. At each
passage, brain homogenates of the suckling mice were
inoculated intracerebrally to adult mice. None of the adult
mice developed rabies and no rabies virus antigens were
detected in their brains. No pathogenic revertants were
detected from these passages [26].
After 10 consecutive passages in BSR cells (a clone of
BHK-21 cells), the SAG2 virus was injected intracerebrally
to five adult mice. No deaths were recorded. The nucleo-
tide sequence of the site III region of the virus stock
was checked. Only the glutamic acid in position 333
was detected [17].The genetic stability of the SAG2 strain was thus dem-
onstrated in vivo (mice) and in vitro. Significantly, the
SAG1 strain was already very stable, since only one of 18
adult mice died after intracerebral inoculation, following
the first passage in suckling mouse brain, and none died
after the second and third passages.
2.3 SAG2 bait
A liquid suspension of the SAG2 strain, with a titer ≥ 108
CCID50/dose (CCID50 = Cell Culture Infective Dose 50%)
is contained in a PVC/aluminium blister which is embed-
ded in a bait. The bait is made from a mixture of fat as the
vehicle, fish meal and natural fish aroma for palatability,
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polymer to provide mechanical resistance needed for
dropping from the aircraft or helicopter, and tetracycline
(150 mg/bait) as a biological marker for uptake. The size
of the SAG2 bait is 4.9 × 4.4 × 1.5 cm and its maximum
weight is 28.1 g (Figure 2). Vaccine baits are stored in a
freezer between −40 °C to −20 °C and protected from
light.
Since baits are released in the environment and may
be touched by humans, SAG2 bait and blister are labelled
with “Rabies vaccine, do not touch” (Figure 2). In addition,
a phone number is provided on the blister and the bait, to
provide information to persons who may find a bait by
accident.
Since the risk of rabies cannot be eliminated completely,
post-exposure prophylaxis (PEP) is necessary in case of
contact with the SAG2 vaccine (WHO category II of
human contact: nibbling of uncovered skin, minor
scratches or abrasions without bleeding [27]). The im-
pact of OV campaigns on the uptake of vaccine baits
and contamination of people was assessed in France
during 1992-1993. During this period, 4.4 million vaccine
baits were distributed. A total of 71 people found and han-
dled a bait (48 had a contact with a SAG1 bait and 23 with
a V-RG bait) and 38 received PEP (31 for SAG1 and 7 for
V-RG). No clinical consequences or serious incidents were
recorded [28].
2.4 Resistance of SAG2 bait and thermostability
Since most baits are dropped from aircraft, it was import-
ant to demonstrate the mechanical resistance of the SAG2
bait. No damage was observed in SAG2 baits distributed
by helicopter onto solid ground either at a speed of
180 km/h and an altitude of 60 to 100 m, or at a speed
of 160 km/h and an altitude of 130 m [26].Figure 2 SAG2 Vaccine bait. This figure shows the bait, the PVC/
aluminium blister containing the liquid suspension of the SAG2
strain. SAG2 bait and the blister are both labelled with “Rabies
vaccine, do not touch”.Baits are resistant in water and not degraded by rain-
fall. By plunging baits into water for 4 days at 25 °C, a
negligible weight gain of 0.2% and partial bleaching
were observed [26]. The melting point of the bait is
56 °C [26]. Baits can be stored without any significant
change in volume, pH, sterility and virus titer at −20 °C
and −40 °C for 2 years, and at 4 °C or 25 °C for up to
7 days [26], following the recommendations of the
EDQM (Pharmacopoeia) and EC [29].
The thermostability of the SAG2 vaccine has been
confirmed in the field. The stability of the liquid form of
the SAG2 strain placed in chicken head baits (such baiting
highly appetent for fox is no more used in Europe) was
tested in Zimbabwe: the titre decreased by l log10 CCID50
within 3 days (at sunshine temperatures in July and
October ranging from 25 °C to 30 °C) when the
chicken head baits were placed under grass or soil, but
underwent marked titre loss when baits were placed in
the sun or shade without covering vegetation [30].
Through a FAIR project (CT 97-3515 “Wildlife vaccin-
ation against rabies in difficult and emergency situations
and its potential impact on the environment”), different
trials were conducted during 1999 and 2000 in Belgium,
France, Germany and Italy to assess the stability of all vac-
cine baits (V-RG, SAG2, SAD B19, SAD P5/P88) available
in the EU [29]. At temperatures < 30 °C, which are usually
observed when baits are distributed during spring and
autumn, vaccine titres remained stable during a 3-week
observation period for all baits. In contrast, titre losses
were significant for all attenuated vaccines when tempera-
tures exceeded 30 °C. In addition, the bait casing of SAD
B19 and SAD P5/88 disintegrated more or less completely
when exposed to high temperatures (30-35 °C) and rain.
The bait casing of the V-RG was more stable, and the
SAG2 casing showed an intermediate resistance [29].
3. Pathogenicity of the SAG2 strain in wildlife
A complete absence of pathogenicity of the SAG2 strain
was demonstrated in adult mice when administered by
various routes and doses [17]. The safety of the SAG2
strain by the oral route was confirmed in the dog and
the cat when administered at a high (109 PFU) dose [31].
3.1 Target species
The safety of the SAG2 strain in the fox and raccoon
dog (Table 1) was assessed under controlled laboratory
conditions before release in the field according to the re-
quirements of the EDQM [32] and recommendations of
WHO [27]. In most studies, the SAG2 strain was admin-
istered in a liquid form by direct instillation into the
mouth to ensure that the entire dose was administered.
Seronegative foxes received by direct instillation into
the mouth ten times (109.0 PFU/animal) or more than
60 times the recommended dose (109.8 CCID50/animal)
Table 1 Summary of the safety data after oral administration of high doses of SAG2 vaccine to foxes and raccoon dogs



















Fox 10 p.o. (6 months
to 2.5 years)
109.8 CCID50 183 days 0/10 0/10 (D0, D1,
D3, D7)
0/10 0/10 10/10 [26]







1010.0 CCID50 60 days 0/5 0/5 0/5 5/5 [35]
5 p.o. bait (6 months) 109.9 CCID50 60 days 0/5 0/5 0/5 5/5
p.o. = per os, D = day, p.f.u. = plaque forming units, CCID50 = cell culture infective dose 50%.
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during the 6-month observation period. No virus excre-
tion was detected in any saliva samples collected 1, 3 and
6-7 days after vaccination. All brain samples (hippocam-
pus, medulla oblongata, cortex) and salivary glands from
vaccinated foxes were negative for rabies virus antigen
detection (by the direct immunofluorescence test) or for
rabies virus isolation, by inoculation in neuroblastoma
cells [26].
The safety of a repeated administration of a field dose
was also evaluated in the fox. Fifteen seronegative foxes
consumed one (n = 5 animals), two (n = 5) or three (n = 5)
baits on 3 consecutive days [26]. The foxes remained
healthy during the 32-day observation period. No rabies
virus was detected in any brain, salivary glands or tonsils
by the direct immunofluorescence test and cell culture in
any animal [26]. Thus, in the event of the ingestion of
several baits in the field, no harmful effects were expected.
The spread of the SAG2 vaccine strain was also studied.
The SAG2 strain is a modified live-rabies virus, and as are
most enveloped viruses, the virus is sensitive to inactivation
by acids and bases, ultraviolet light, heat, repeated freeze-
thaw cycles and disinfectants such as mild soap solutions
[33]. Thus the SAG2 virus is likely to be inactivated in the
event of release in the environment. Transmission from
animal to animal could only occur through saliva, and not
through faeces, because the vaccine virus is inactivated
rapidly in the stomach [34]. In consequence, the spreading
of the SAG2 strain was studied through saliva swabs and
in salivary glands. No sample was detected positive for ra-
bies virus in any fox after the administration of high or re-
peated doses of the SAG2 strain (see previous paragraph).
The safety profile observed in the fox was confirmed
in the raccoon dog. A SAG2 suspension was instilled in
the mouth of five raccoon dogs (1010.0 CCID50/animal),
and each of five other raccoon dogs consumed a SAG2
bait (109.9 CCID50/bait) [35]. All raccoon dogs remained
healthy during the 60-day observation period. Brains
and salivary glands from all animals were negative for
rabies virus. The safety of the oral administration of
SAG2 vaccine was demonstrated in two species of jackal(side-striped jackal and black-backed jackal) either by dir-
ect instillation (the highest dose was 107.5 CCID50/animal)
or included in a bait (the highest dose was 108.0 CCID50/
animal) [30]. In addition, all saliva swabs collected 1, 3
and 7 days after vaccine instillation were negative for
rabies virus detection except for a pool of saliva swabs
collected on day 3 from three black-backed jackals
inoculated with the highest dose (107.5 TCID50/animal)
of the vaccine [30].
3.2 Non target species
Any animal species sharing the habitat of the target
species may ingest vaccine baits. The most relevant
and common non-target species were selected in dif-
ferent countries and inoculated with the SAG2 strain
(Table 2). The SAG2 studies were conducted according
to the guidelines of WHO for the safety testing of
modified live-rabies vaccines for use in wild carnivores
[4] and according to the European Pharmacopoeia
[32]. For some trials performed in countries where the
SAG2 vaccine was intended to be used in dogs, recom-
mendations given by WHO for safety testing of oral
vaccines for domestic dogs were applied (wherever
possible) because they are more stringent, dogs being
in contact with humans [5,6]. In particular, modified
live-virus vaccines for domestic dogs must be safe for
local wild and domestic non-target animal species when
administered orally at 10 times the recommended dose
used in the field, and there should be no, or minimal, ex-
cretion of virus following vaccination and there should be
no persistent infection by the vaccine virus. In addition,
vaccines should be assessed and found safe in non-human
primates.
The safety of the SAG2 strain was demonstrated in
various European [36], African [37-39] and Arctic [40]
non-target species including rodents (mouse, rat, vole,
squirrel, gerbil, jerboa, meriones), carnivores (coyote,
ferret, civet, mongoose, badger, genet), non-human pri-
mates (Chacma baboons), other mammals (hedgehog,
wild boar, domestic goat, cow), and diurnal and noc-
turnal birds (crow, rook, buzzard, kite, owl). All species
Table 2 Summary of safety studies in various target and non target species







Rodentia Cricetidae Common vole 9 p.o. 107.7 PFU (0.05 mL) 78 days [36]
(Microtus arvalisà) 9 i.m. 107.5 PFU (0.03 mL) 78 days
Rodentia Cricetidae Bank vole (Myodes glareolus) 11 p.o. 107.7 PFU (0.05 mL) 78 days [36]
11 i.m. 107.5 PFU (0.03 mL) 78 days
Rodentia Cricetidae European water vole 2 p.o. 107.7 PFU (0.05 mL) 78 days [36]
(Arvicola amphibius)
Rodentia Cricetidae Tundra vole 9 p.o. 107.16 MICLD50 (0.03 mL) 46 days [40]
(Microtus oeconomus)
Rodentia Cricetidae Northern red-backed
vole (Myodes rutilus)
10 p.o. 107.16 MICLD50 (0.03 mL) 46 days [40]
Rodentia Sciuridae Arctic ground squirrel 9 p.o. 107.68 MICLD50 (0.1 mL) 46 days [40]
(Spermophilus parryii)
Rodentia Muridae Field mouse 15 p.o. 107.5 PFU (0.05 mL) 78 days [36]
(Apodemus flavicollis 15 p.o. 107.7 PFU (0.03 mL) 78 days
or Apodemus sylvaticus) 10 i.c. 107.5 PFU (0.03 mL) 78 days
Rodentia Muridae Norway rat 15 p.o. 107.44 PFU (0.05 mL) 42 days [36]
(Rattus norvegicus) 15 i.m. 107.44 PFU (0.05 mL) 42 days
Rodentia Muridae Multi-mammate mouse 39 p.o. 108.0 TCID50 (0.1 mL) ≥ 90 days [37]
(Mastomys natalensis)
Rodentia Muridae Bushfelt gerbil 26 p.o. 108.0 TCID50 (0.1 mL) ≥ 90 days [37]
(Gerbilliscus leucogaster)
Rodentia Muridae North African gerbil
(Gerbillus campestris)
32 i.m. 107.0 - 108.5 TCID50
(0.03-0.1 mL)
60 days [38]
Rodentia Muridae Merion 14 p.o. 108.2 - 109.2 TCID50
(0.05-0.5 mL)
60 days [38]
(Meriones) 14 i.m. 107.0 - 108.5 TCID50
(0.03-0.1 mL)
60 days
Rodentia Dipodidae Greater Egyptian Jerboa
(Jaculus orientalis)
2 i.m. 107.0 TCID50 (0.03 mL) 60 days [38]
Carnivora Canidae Red fox (Vulpes vulpes) 10 p.o. 109.8 TCID50 (2 mL) 183 days [26]
Carnivora Canidae Black-backed jackal 3 p.o. 107.5 TCID50 (1 mL) 180 days [30]
(Canis mesomelas) 3 p.o. 106.5 TCID50 (1 mL) 180 days
Carnivora Canidae Side-striped jackal 3 p.o. 107.5 TCID50 (1 mL) 180 days [30]
(Canis adustus) 3 p.o. 106.5 TCID50 (1 mL) 180 days
Carnivora Canidae Golden jackal (Canis aureus) 8 p.o. 109.5 TCID50 (1 mL) 90 days [38]













Carnivora Canidae Domestic dog
(Canis familiaris)
21 p.o. 109.5 TCID50 (1 mL) 90 or
180 days
[38]
Carnivora Canidae Wild dog (Lycaon pictus) 4 p.o. 108.0 TCID50 (1 mL) 634 days [39]
Carnivora Canidae Raccoon dog 5 p.o. 1010.0 CCID50 (1.7 mL) 60 days [35]
(Nyctereutes procyonoides) 5 p.o. 109.8 CCID50 (bait)
Carnivora Felidae Domestic cat (Felis catus) 10 p.o. 1010 TCID50 (1 mL) 180 days [26]
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Table 2 Summary of safety studies in various target and non target species (Continued)
Carnivora Felidae Domestic cat (Felis catus) 11 p.o. 109.5 TCID50 (1 mL) 90 days [38]
Carnivora Mustelidae Domestic ferret 4 p.o. 108.17 PFU (2 mL) 37 days [36]
(Mustela putorius furo) 4 i.m.
Carnivora Mustelidae Honey badger
(Mellivora capensis)
6 p.o. 109.0 TCID50 (1 mL) ≥ 90 days [37]
Carnivora Mustelidae European badger (Meles meles) 5 p.o. 108.17 PFU (2 mL) 35 days [36]
Carnivora Viverridae African civet 6 p.o. 109.0 TCID50 (1 mL) ≥ 90 days [37]
(Civettictis civetta)
Carnivora Viverridae Large-spotted genet 6 p.o. 109.7 TCID50 (1 mL) ≥ 90 days [37]
(Genetta tigrina)
Carnivora Herpestidae Slender mongoose 6 p.o. 109.0 TCID50 (1 mL) ≥ 90 days [37]
(Galerella sanguinea)
Carnivora Procyonidae Raccoon (Procyon lotor) 5 p.o. 109.0 TCID50 (1 mL) 30 days [55]
Carnivora Mephitidae Striped skunk
(Mephitis mephitis)
5 p.o. 109.0 TCID50 (1 mL) 30 days [55]
Primates Cercopithecidae Chacma baboon (Papio ursinus) 10 p.o. 109.0 TCID50 (1 mL) ≥ 90 days [37]
Erinaceomorpha Erinaceidae Western European hedgehog
(Erinaceus europaeus)
6 p.o. 107.87 PFU (1 mL) 57 days [36]
Artiodactyla Suidae Wild boar (Sus scrofa) 5 p.o. 108.88 PFU (2 mL) 35 days [36]
Artiodactyla Bovidae Domestic goat (Capra hircus) 6 p.o. 108.8 PFU (2 mL) 35 days [36]
Artiodactyla Bovidae Cow (Bos primigenius) 5 p.o. 1010.0 CCID50 60 days [26]
Passeriformes Corvidae Carrion crow (Corvus corone) 7 p.o. 108.66 PFU (1.5 mL) 33 days [36]
Passeriformes Corvidae Pied crow (Corvus albus) 6 p.o. 109.0 TCID50 (1 mL) ≥ 90 days [37]
Passeriformes Corvidae Rook (Corvus frugilegus) 8 p.o. 108.66 PFU (1.5 mL) 33 days [36]
Falconiformes Accipitridae Buzzard (Buteo buteo) 7 p.o. 108.18 PFU (1.0 mL) 33 days [36]
Falconiformes Accipitridae Red kite (Milvus milvus) 1 p.o. 108.18 PFU (1.0 mL) 33 days [36]
Strigiformes Strigidae Tawny owl (Strix aluco) 1 p.o. 108.18 PFU (1.0 mL) 33 days [36]
Strigiformes Strigidae Long-eared owl (Asio otus) 2 p.o. 108.18 PFU (1.0 mL) 33 days [36]
Strigiformes Tytonidae Barn owl (Tyto alba) 1 p.o. 108.18 PFU (1.0 mL) 33 days [36]
TCID50: median tissue culture infectious doses.
p.f.u.: plaque forming units.
MICLD50: mouse intracerebral lethal dose (10
7.2 MICLD50 equivalent to 10
9.0 CCID50).
p.o. = per os, i.m. = intramuscularly.
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the mouth, and for some species by intramuscular or
intracerebral route. None of the inoculated animals
showed specific lesions or died of rabies during the
observation period. Importantly, no pathogenicity
of the SAG2 strain administered orally at a high dose
(109 TCID50/animal) was observed in the baboon [37].
Different studies in non target species showed that
the persistence of the SAG2 virus in the oral cavity is
very limited or even nil in non target species. In a
study performed in Zimbabwe [37], saliva swabs were
collected from all animals (except rodents and crows),
1, 3 and 7 days after vaccine administration. Only
one saliva sample was detected positive (at a very low
virus concentration) in one genet 1 day after vaccine
administration [37]. The presence of a residualvaccine inoculum 24 h after oral administration of
the SAG2 strain to the genet could not be excluded.
No persistent infection after administration of the
SAG2 strain was detected in any of the brain and sal-
ivary glands (or saliva) from civets, or for some ani-
mals in tonsil tissues at the end of the observation
period [36,37].
In most studies, at least two WHO/OIE methods were
used for the detection of rabies virus, i.e. the direct
fluorescent antibody test (FAT) [41] on smears of brain
or salivary glands, and the inoculation of brain or saliv-
ary glands homogenates to cell culture [42] or intracere-
brally to 1-3 day old mice [43].
The safety of a lyophilized form of the SAG2 vaccine
included in a bait was also demonstrated in the northern
collared lemming, Dicrostonyx groenlandicus [44].
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in controlled laboratory trials
Although the best approach for testing a vaccine is to
evaluate it in the field, it is necessary to first determine
efficacy under controlled conditions.
SamplesBlood samples from foxes and raccoon dogs were
collected in the field and in ANSES-Nancy’ experimental
station (Atton, Meurthe-et-Moselle département, France).
The facility has been approved by French Veterinary
Services on 19 of April 2011 (approval C-54-431-1).
Experiments and husbandry were conducted following
European Directive, 2010/63/EU and French regulations
on ethics in animal experimentation.
The immunogenicity of the SAG2 strain was then
assessed in different wild animal species (Table 3).
Groups of ten 6-week old mice were inoculated intra-
cerebrally with 30 μL of various dilutions of the SAG2
strain (equivalent to 1.5 – 2.5 – 3.5 – 4.5 – 5.5 and 6.5
log PFU/mouse). Four weeks later, mice were challenged
with 200 LD50 of the CVS strain of rabies virus in the
masseter muscle. From a dose of 3.5 log PFU/mouse, all
mice were protected [17].
4.1 Red fox
Red foxes (Vulpes vulpes) are responsible for the main-
tenance and spread of rabies in the subarctic and
north-eastern parts of North America, in subarctic
Asia, and in central and eastern Europe.
Two experiments [26,31] demonstrated that the SAG2
strain administrated by instillation into the mouth at
different doses (108 (n = 5), 107.5 (n = 18), 107 (n = 5)
PFU/animal) induced a full protective immunity after a
rabies virus challenge performed 29, 85, 220 or 303 days
after oral instillation (Table 3). In a third experiment
[26], different doses of the SAG2 vaccine (107.0, 108.0
and 109.0 CCID50/bait, n = 5 animals/dose) included in a
bait were administered to foxes. Baits were consumed
within 1 hour by 13 of 15 foxes, showing the attractiveness
of the bait. All vaccinates seroconverted, a dose-response
relationship was observed between the mean neutralizing
antibody titers and the dose of vaccine (1.7, 2.5 and
5.1 IU/mL in the 107.0, 108.0 and 109.0 CCID50 dosage
groups, respectively). All controls succumbed to rabies
virus challenge performed 30 days after vaccination,
whereas high survival rates (80%, 80% and 100% in the
107.0, 108.0 and 109.0 CCID50 dosage groups) were ob-
served in challenged vaccinates (Table 3). This study
showed that the minimal protective dose is probably
below the lowest dose tested.
The last study [26] was conducted according to the
requirements of the European monograph (0746) [32].
Twenty-five foxes received a SAG2 bait at the recom-
mended dosage (108 CCID50/bait). All animals (25 vacci-
nates and 10 controls) were challenged 180 days aftervaccination. All controls and three of 25 vaccinates devel-
oped clinical signs and died of rabies (Table 3). Two of
three not protected foxes did not eat the bait. No serocon-
version was observed in the three vaccinates which were
not protected, while all survivors except one vaccinate ser-
oconverted after vaccination.
These different trials demonstrated the protective effect
of SAG2 vaccine bait in controlled laboratory conditions.
Obviously, the puncture of the capsule is a determinant
factor for ensuring the protection.
Although seroconversion is usually associated with
immunity against a rabies virus challenge, in the vari-
ous experiments some animals did not seroconvert and
were protected after challenge. A study showed that a
T-cell specific memory response was detected in foxes
6 months after the oral instillation of a field dose of
SAG2, suggesting that the SAG2 vaccine can stimulate
cell-mediated mechanisms in foxes [45].
A long-lasting protective immunity was demonstrated in
red foxes immunized with the SAG1 strain administered by
instillation in the oral cavity (107 TCID50/dose) up to
18 months after vaccination [46]. Since SAG1 and
SAG2 strains have a comparable efficacy profile, it may
be hypothesized that the SAG2 strain is also able to in-
duce a long-term protection of red foxes lasting for the
average life of a fox. However, a bi-annual vaccination is
required in the field, in particular to target juveniles
during spring [29].
4.2 Raccoon dog
The raccoon dog (Nyctereutes procyonoides), a member
of the Canidae, has been introduced by the fur industry
from eastern Asia into the European part of Russia
around 1920. This species has spread rapidly in Europe
due to its high rate of reproduction, extreme adaptabil-
ity, omnivorous habits and capacity to hibernate [47].
Raccoon dogs are now common in the Baltic States,
many parts of eastern Europe and Finland with a density
even higher than that of the red fox. Its presence has
been reported in Germany, Sweden, Norway, France,
The Netherlands, Switzerland, Poland and Austria [47].
The raccoon dog has become a major factor in the epi-
demiology of rabies in the Eastern and Northern Europe
[47,48] and is now the second most important wildlife
species – after the red fox – infected with rabies [49].
Faced with the increase of rabies cases in raccoon dogs,
specific investigations to assess the efficacy of OV were
conducted under controlled conditions (Table 3). SAG2
baits (one bait/animal) at a field dose (108.15 CCID50/dose)
were given to 29 raccoon dogs [35]. Baits were consumed
rapidly by most animals (the other animals were instilled
in the oral cavity with the content of the bait). All vacci-
nated raccoon dogs developed high neutralizing antibody
titers. All vaccinates (n = 29) were fully protected against a
Table 3 Summary of the efficacy data in different target species after vaccination with SAG2 vaccine administered either by
direct instillation in the mouth or by bait consumption











Red fox ± 12 months 5 p.o. 107 p.f.u. 29 days 5/5 5/5 0/5 [31]
± 12 months 5 p.o. 108 p.f.u. 5/5 5/5 0/5
± 12 months 5 controls - 0/5 0/5 5/5
Red fox ± 9 months 6 p.o. 107.5 p.f.u. 85 days 6/6 6/6 0/6 [26]
± 9 months 2 controls - 0/2 0/2 2/2
± 9 months 5 p.o. 107.5 p.f.u. 220 days 5/5 5/5 0/5
± 9 months 1 control - 0/1 0/1 1/1
± 9 months 6 p.o. 107.5 p.f.u. 303 days 6/6 6/6 0/6
± 9 months 2 controls - 0/2 0/2
Red fox 13-14 months 5 p.o. (bait) 107.0 CCID50 30 days 5/5 4/5 1/5 [26]
5 p.o. (bait) 108.0 CCID50 5/5 4/5 1/5
5 p.o. (bait) 109.0 CCID50 5/5 5/5 0/5
2 controls - 0/2 0/2 2/2
Red fox 6.4 months to
4.5 years
25 p.o. (bait) 108.0 CCID50 180 days 21/25 22/25 3/25 [26]
10 controls - 0/10 0/10 10/10
Raccoon
dog
6 months 29 p.o. (23 bait,
6 instill)
108.15 CCID50 201 days 29/29 28/28 0/28 [35]
6 months 12 controls - 0/12 0/11 11/11
Side-striped
jackal
≥ 9 months 3 p.o. (instill) 106.5 CCID50 6 months 2/3 3/3 0/3 [30]
≥ 9 months 3 p.o. (instill) 107.5 CCID50 2/3 2/3 1/3




≥ 9 months 3 p.o. (instill) 106.5 CCID50 6 months 3/3 3/3 0/3 [30]
≥ 9 months 3 p.o. (instill) 107.5 CCID50 3/3 3/3 0/3
≥ 9 months 2 controls - 0/2 0/2 2/2
Side-striped
jackal
≥ 9 months 5 p.o. (bait) 108.25 CCID50 30 days 5/5 5/5 [30]
≥ 9 months 5 p.o. (bait) 107.25 CCID50 3/5 3/5
≥ 9 months 5 controls 0/5 0/5
Golden
jackals
≥ 9 months 14 p.o. (bait) 108.0 CCID50 160 days 11/14 12/14 (85.7%) [50]
≥ 9 months 10 controls - 0/10 0/10 (0%)
Arctic fox 10 p.o. (bait) 107.75 SMICLD50 7 weeks 10/10 10/10 0/10 [52]
4 controls - 0/4 1/4 3/4
Raccoon adult 5 p.o. (instill) 109.0 TCID50 30 days 3/5 5/5 0/5 [55]
adult 5 controls - 0/5 0/5 5/5
Striped
skunk
adult 5 p.o. (instill) 109.0 TCID50 30 days 2/5 5/5 0/5 [55]
adult 5 controls - 0/5 0/4* 4/5
Coyotes unknown 4 p.o. (liquid
bait form)
107.3 TCID50 30 days 2/4 3/4 1/4 (Rupprecht et al.:
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Table 3 Summary of the efficacy data in different target species after vaccination with SAG2 vaccine administered either by
direct instillation in the mouth or by bait consumption (Continued)
unknown 4 p.o. (liquid
bait form)
108.3 TCID50 3/4 4/4 0/4
unknown 4 p.o. (liquid
bait form)
109.6 TCID50 4/4 4/4 0/4
unknown 5 p.o. (lyophilized
bait form)
106.9 TCID50 3/5 2/5 3/5
unknown 5 p.o. (lyophilized
bait form)
107.2 TCID50 3/5 4/5 1/5
unknown 5 p.o. (lyophilized
bait form)
108.3 TCID50 5/5 5/5 0/5
unknown 5 controls 0/5 0/5 5/5
*1 control skunk died following sedation on day 83 and was negative for rabies.
p.o. = per os, p.f.u. = plaque forming units, CCID50 = cell culture infective dose 50%, TCID50 =median tissue culture infectious dose 50%, SMICLD50 = suckling mouse
intracranial 50% lethal dose.
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ation, while all controls (n = 12) succumbed to rabies [35].
SAG2 vaccine baits are attractive for raccoon dogs and in-
duce a protective immunity against rabies.4.3 Jackal
There are three species of jackals in Africa and Asia. In
Africa, jackals are one of the major wildlife rabies vectors
[27]. In Zimbabwe, a quarter of rabies cases are reported
in jackals, especially in the side-striped (80% of jackal
cases) and black-backed jackal [30].
The efficacy of the SAG2 vaccine was assessed in these
two species [30]. SAG2 was administered either by direct
oral instillation at two doses (106.5 or 107.5 CCID50/animal,
n = 3 animals/dose) (Table 3) or placed into blisters
stapled under the skin of chicken heads at two doses
(107.25 or 108.25 CCID50/animal, n = 5 animals/dose).
All animals were challenged either 1 month (vaccinated
with a bait) or 6 months (vaccinated by instillation) after
vaccination using a rabies virus field strain of side-striped
jackal (salivary glands). Most jackals seroconverted after
vaccination and high survival rates were observed after
direct oral administration in both species [30].
These promising results were confirmed in the golden
jackal, Canis aureus (Table 3). The golden jackal is found
from Yugoslavia and Greece to Burma in Asia, including
Turkey and India, the Middle East and southern parts of
the Arabian Peninsula [50]. Between 1950 and 1970, the
golden jackal represented a major reservoir of wildlife in
Israel [50]. Golden jackals received SAG2 baits and were
challenged 160 days after vaccination with a local rabies
virus isolate from a jackal [50]. Vaccinated animals
achieved a seroconversion rate of 79% 150 days after
vaccination, and high protection rate after challenge was
observed (86%). In contrast all controls succumbed to
rabies [50].4.4 Arctic fox
The arctic fox (Alopex lagopus) is the primary rabies res-
ervoir in most circumpolar regions [51]. Since freezing
temperatures are observed throughout the year in arctic
regions, the liquid form of the SAG2 vaccine was not
adapted, because it could freeze and passed directly into
the stomach without a step of absorption through the
oral mucosa. To assess the efficacy of the SAG2 vaccine,
the SAG2 vaccine was lyophilized in the form of a wafer
coated by a thin layer of ground beef. Ten arctic foxes
received a prototype SAG2 bait, at 107.75 SMICLD50
[52]. All baits were consumed rapidly. Oral swabs col-
lected 1, 24, 48 and 72 h after bait intake were all nega-
tive for rabies virus. All vaccinates seroconverted by
2 weeks after vaccination and had neutralising antibody
titers (≥ 0.5 IU/mL) just before challenge. All vaccinates
and four controls were challenged 7 weeks after vaccin-
ation with an arctic red fox rabies virus strain (isolated
in Alaska). All vaccinates survived rabies virus challenge
whereas three of four controls died of rabies [52].4.5 Raccoon and skunk
The raccoon (Procyon lotor) and striped skunk (Mephitis
mephitis) are major wildlife rabies reservoirs in North
America [53,54]. Although SAG2 is not licensed in North
America, its utility for local wildlife OV was assessed. Five
raccoons and five skunks received by instillation in the
mouth a suspension of SAG2 (109 TCID50/animal) [55]
(Table 3). Three of five raccoons and two of five skunks
seroconverted after vaccination. All animals were chal-
lenged 30 days after vaccination with either a raccoon
rabies virus pool from salivary glands or a skunk rabies
virus isolate. All vaccinated animals resisted challenge
while all control raccoons (n = 5) and all control skunks
(4 out of 4, the 5th control died following sedation and
was negative for rabies virus) died of rabies.
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In South Africa, the yellow mongoose is the main reservoir
of rabies [56]. The immunogenicity of the SAG2 vaccine
was evaluated in mongooses vaccinated by oral instillation:
13 of 15 vaccinated mongooses were protected after a
virulent rabies virus challenge [6].4.7 Coyote
A dose response experiment was conducted to assess
the efficacy of SAG2 baits in coyotes (Rupprecht et al.:
Efficacy of SAG2 for oral vaccination of coyotes against
rabies, unpublished). Different doses of the liquid form
(107.3, 108.3, 109.6 TCID50/bait, n = 4 coyotes per dose) or
lyophilized bait form (106.9, 107.2, 108.3 TCID50/bait, n = 5
coyotes per dose) of SAG2 vaccine were administered
(Table 3). Five coyotes served as controls. High serocon-
version rates were observed. On day 30, all coyotes were
challenged with a coyote street rabies virus. All 5 controls
succumbed to challenge, as did only one of 12 animals from
the group vaccinated with the liquid bait form (at the low-
est dilution) and 4 of 15 from the group vaccinated with
the lyophilized bait form (3 at the lowest dilution, and 1 at
the next concentration, but none at the highest concentra-
tion). Thus, SAG2 vaccine used at a field concentration of
108.3 TCID50 could be used for the protection of coyotes
against rabies (Rupprecht et al.: Efficacy of SAG2 for oral
vaccination of coyotes against rabies, unpublished).4.8 Ethiopian wolf
The Ethiopian wolf (Canis simensis) is highly endangered
and the rarest canid in the world, with only about 420
adults living in the Ethiopian highlands [57]. Rabies out-
breaks occurred during 1991, 2003 and 2008/2009 with a
high mortality rate of up to 75% of the affected population
[57]. Emergency parenteral vaccination of several packs of
Ethiopian wolves was initiated during 2003 and 2008-09
to contain outbreaks [57]. However, parenteral vaccination
is logistically complex and costly. Thus, during 2011
another approach was considered [57,58]. A small pilot
study was conducted to assess the efficacy of SAG2
vaccine. The animals received a SAG2 vaccine blister
inserted into goat/sheep meat. Among the four animals
which consumed bait, three seroconverted [57]. All
these wolves were still alive and healthy almost one year
after vaccine administration (Chris Gordon, personal
communication).
Other studies conducted to evaluate the safety of the
SAG2 strain in different species showed that after oral
administration, rabies virus neutralizing antibodies were
produced in the ferret, badger, wild boar, mouse, meriones,
civet, mongoose, jackal, wild dogs (Lycaon pictus), captive-
bred baboon, and raptors, but none in the goat, Norway
rat, vole or Corvidae [36-39].Thus, the efficacy of SAG2 baits was demonstrated
according to the EU requirements for the fox and raccoon
dog. Encouraging results were obtained in the jackal, rac-
coon, skunk, mongoose and Ethiopian wolf.
5. Efficacy of SAG2 in the field
The SAG2 vaccine (RABIGEN®, Virbac Laboratories,
Carros, France) has been registered in the 28 countries
of the EU (European Medicines Agency registration)
for OV administration in baits to foxes and raccoon
dogs [26].
The SAG2 vaccine has contributed substantially to the
elimination of rabies in several European countries. The
efficacy of OV is assessed by comparing the prevalence
of rabies in vaccinated areas, the proportion of fox and
raccoon dog populations which consume the bait (revealed
through a tetracycline biomarker) and immunisation rates
by antibody measurement [27,29].
The number of campaigns and associated costs ne-
cessary to reach the rabies free status depended on
various parameters mainly linked to the planning and
the implementation of OV, the rabies situation and
control programmes in neighbouring countries and the
level of surveillance. The strategies of oral vaccination
using SAG2 vaccine were different depending on the
countries (as exposed in the following paragraphs).
5.1 Switzerland
The fox rabies epidemic, originating from eastern Europe,
reached Switzerland during 1967 [59]. Initial attempts
to stop disease progression consisted in reducing fox
population (by gassing in fox dens and shooting foxes
at the den). This strategy did not succeed in preventing
outbreaks and rabies spread almost throughout the terri-
tory. A peak in rabies cases was observed during 1976
(1738 cases) with 73% of cases reported in foxes [59].
Switzerland was the first European country to initiate a
limited field trial of OV of foxes during October 1978 in
the lower Rhône Valley (canton of Valais). The disease did
not cross the resulting barrier (approximately 60% of foxes
were believed to be immune). The OV campaigns were ex-
tended gradually. Capsules of SAD Bern vaccine included
in chicken head baits were distributed manually during
spring and autumn [59,60]. The country was divided into
epidemiologic compartments delineated by natural (such
as high mountain ranges, rivers, lakes) and artificial obsta-
cles to the spread of rabies. The strategy adopted for OV
was to treat infected compartments one by one until they
were free of rabies, to protect the entrances to rabies-free
by threatened compartments [60]. The number of rabies
cases decreased to 25 during 1990 (Figure 3), and a major
part of the country was freed from rabies, except for one
area in the Jura mountains close to the French border
[61-63]. A new outbreak of rabies occurred during 1991
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spring 1991, SAD Bern chicken head baits were replaced
by industrially manufactured fishmeal/beef SAG1 baits.
SAG1 and SAG2 baits were used during 1994, and by
1995 SAG2 replaced SAG1 baits (Figure 3). Rabies cases
remained high (225 cases during 1994), so the vaccination
strategy was adjusted. The bait density was increased from
15 to 25 baits per km2 to take into account a larger fox
population and density, two vaccination campaigns were
conducted within 1 month in any new vaccination area
and baits were distributed at fox den entrance (6 to 10
baits/fox den) in an additional campaign during early
summer to immunize young foxes [61-63]. Cross-border
vaccination efforts limited the risk of reinfection from
neighbouring countries. Vaccination was also contin-
ued until at least 2 years after recording the last case of
rabies related to the fox rabies epidemic. As a conse-
quence, the number of rabies cases dropped from 23 to
6 during 1995 and 1996, respectively [61-63]. Since
1997, i.e. less than 2 years after initiation of this new
strategy, no indigenous rabies cases were reported.
Switzerland was declared rabies-free during spring
1999 [61-63].
Comparing bait uptake and seroconversion rates, during
1995 and 1996, 66% of foxes tested were detected as posi-
tive for tetracycline and 50% had rabies virus neutralizing
antibodies [63]. The proportion of foxes positive for tetra-
cycline and neutralizing antibodies was higher in adults
(75% and 59%, respectively) than young foxes (58% and
40%, respectively). Seasonal variations were observed in
young foxes (< 1 year of age) with a higher bait uptake
and seroconversion rate after the autumn campaigns than
the spring. Interestingly, the den baiting strategy led to
a significant increase in tetracycline and seroconversion
rates in young foxes (64% and 50%, respectively), reaching
values close to that observed in adults [63].
5.2 France
Fox rabies invaded north-eastern France during 1968.
The first case was reported in Moselle, near the German
border [64]. From 1968 to 1974, rabies progressed at a
mean annual speed of 30-40 km, and then the infectious
wave front slowed [62]. During 1981, old foci were reac-
tivated and rabies increased. From 1986 to 1988, the first
OV campaigns were conducted in the Lorraine region and
the French Jura and Alps in collaboration with Belgium,
Luxembourg and Switzerland [18]. Manual baiting was
used for the first campaigns, and after 1987, aerial
methods were adopted for the distribution of larger
quantities of baits. Since autumn 1988, helicopters flying
at an altitude of 60-100 m and a speed of 180 km/h along
three transect lines per km2 were preferred over lighter
aircrafts [64]. Despite encouraging results, rabies pro-
gressed and crossed the Seine and the Loire rivers. During1989, the infected area covered 140 000 km2, correspond-
ing to the highest case numbers observed in France (4212
terrestrial rabies cases reported) (Figure 3). To protect
south-western France, which was still rabies-free, rather
than vaccinating rabies from the north of Lorraine
(surrounded by heavily infected areas), a continuous
strip (50 km wide) was established during autumn
1990 from the English Channel to the Swiss border
[62]. Rabies OV was extended to the north and the east
towards the borders with Belgium, Luxembourg and
Germany [62]. The OV campaigns were performed during
autumn and spring in the entire contaminated area (141
700 km2) from autumn 1992 to 1997 [18]. The number
of rabies cases decreased rapidly. From 1997 to 2000,
OV campaigns were conducted along the borders with
Switzerland and with Germany [62]. The last three cases
of rabies (two foxes and one cat) were registered in
Moselle near the German border between November
1997 and December 1998. The cases reported in Figure 3
in 2001, 2002 and 2004 were rabid dogs imported from
countries infected with canine rabies. From 2001 to 2003
and in 2005 (last campaign in autumn), OV was limited to
a border area of 5500 km2 with a bait density of 20 baits/
km2 [18,65]. France has been recognized as free of terres-
trial cases since 2001 [18,62,64]. Since the fox populations
were growing, the bait density was increased from 13
baits/km2 during 1986 to 1995, to 15 baits/km2 during
1995 and 20 baits/km2 since 1997 [65]. Four different vac-
cines were used between 1986 and 1998: SAD B19 was
used from 1986 to 1991, and was gradually replaced by V-
RG, during autumn 1989 and SAG1 from autumn 1990
[64]. The SAG2 vaccine was used for the first time in
France during autumn 1993. Thereafter, SAG1 was re-
placed by SAG2 during spring 1994. More than 3 million
SAG2 baits were distributed from autumn 1993 to 1998.
Overall, during the 1994-1997 period, 74% of foxes (84%
of adults and 60% of fox cubs) were found positive for
tetracycline [26]. The proportion of foxes (all age groups
combined) found positive for tetracycline increased grad-
ually from 50% and 66% after the spring and autumn cam-
paigns during 1994, respectively to 87% and 90% for the
corresponding seasons during 1997. As for Switzerland,
the proportion of foxes found positive for tetracycline was
lower after the spring campaign than after the autumn
during 1995 and 1996 [26]. The increase in the positivity
rate for tetracycline during the 1991-1997 period was
more marked for young foxes (during spring and autumn,
with 35% and 37% during 1994, 81% and 84% during
1997, respectively) that adult foxes (in spring and autumn,
with 89% and 74% during 1994, 93% and 92% during
1997, respectively) [26]. The analysis of fox teeth showed
several tetracycline lines, indicating that multiple baits
were consumed by individual foxes. On average, 2.6 baits




















































































































































































































































































































































Figure 3 Animal rabies cases before and after vaccination campaigns with SAG2 in Switzerland, France, Estonia, Italy. The impact of the
vaccination with SAG2 baits on the number of terrestrial animal rabies cases is illustrated in four countries, Switzerland, France, Estonia and Italy.
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64% of foxes found positive for tetracycline (71% for
adults and 51% for fox cubs) were seropositive for rabies
virus antibodies using an ELISA test [26].
Different strategies have been evaluated in France to
improve the efficacy of OV in the field, such as increasing
the number of vaccine baits distributed during one cam-
paign, performing two distributions at 15-30 days apart
[67], distributing baits at den entrances [68]. Immunising
fox cubs, which account for two thirds of the fox popu-
lation in spring, is a key factor for OV success. A study
conducted during spring 1997 with SAG2 baits showed
that two distributions 2 or 4 weeks apart did not improve
either the bait uptake or seroconversion rates in adults
and in fox cubs. In contrast, a delayed spring distribution
during May or June rather than April increased the sero-
conversion rate in fox cubs [67]. Another study performed
under laboratory conditions confirmed that two successive
oral vaccinations performed 35 days apart did not sig-
nificantly improve the seroconversion rate in foxes, since
the humoral response after rabies challenge (performed
6 months after vaccination) were already high after oneoral administration [45]. This result confirmed that a
single dose of SAG2 vaccine allowed the production of
memory B cells and a long-term anamnestic response
that protected foxes against rabies. Vaccination of fox cubs
by distributing the baits at the entrance of dens allowed
increasing significantly the immunization rate of cubs
(38% versus 17% for controls without distribution at dens).
However, since this type of distribution is costly and time-
consuming, it was only recommended for restricted areas,
where residual foci exist, in addition to the aerial distribu-
tion of baits [68]. In France, where different oral vaccines
were used [64], the benefit of oral vaccination was ob-
tained after the fourth year of the programme and the
highest costs were for preventive vaccination of pets and
prevention in humans [69].5.3 Estonia
The number of rabies cases increased from 74 cases dur-
ing 1995 to 814 cases during 2003 (Figure 3). The red fox
and the raccoon dog were the most frequently infected
wildlife [49]. The first OV programme was conducted on
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Manual distribution of baits showed the feasibility of OV
in this area [70]. During autumn 2005, the first large-scale
OV campaign was implemented in the Northern part of
Estonia from the Western to the Eastern border, including
national islands. From 2006 to 2010, OV campaigns, co-
financed by the EU and the Estonian State Budget, were
conducted twice a year throughout the Estonian territory.
The organization and implementation of these OV
campaigns complied with the recommendations of the
EU [29]. Baits were dropped at a density of 20 baits/km2
using fixed-wing aircraft along parallel flight paths 600 m
apart. Flights took place at an altitude of 100-150 m at an
average speed of 160-180 km/h. As a consequence of
OV, the number of rabies cases dropped dramatically
(Figure 3). The last four rabies cases were detected within
five kilometres of the Estonian–Russian Federation border
in the South-East. No rabies cases were detected since
January 2011. The country was recognized as rabies-free
during April 2013. According to recommendations of
international organisations, all rabies viruses isolated in
areas where SAG2 was used were characterized in the EU
Rabies Reference Laboratory to differentiate vaccine
strains from viruses maintained by wildlife. All field iso-
lates from Estonia belonged to the classical rabies virus
(genotype 1) and were closely related [71,72]. Yearly posi-
tivity rates for tetracycline ranged from 85% to 93% in
foxes and from 82% to 88% in raccoon dogs. Annual im-
munisation rates assessed through an ELISA test ranged
from 34% to 55% in foxes and from 38% to 55% in rac-
coon dogs [72]. Since 2011, to prevent re-infections from
infected neighbouring countries, OV was restricted to buf-
fer zones (total vaccinated area: 9325 km2) at the Russian
and Latvian borders using a bait density of 20 baits/km2.
The 2005-2010 total budget dedicated to rabies control
(expenses for parenteral and oral vaccines, aerial distribu-
tion, surveillance testing, sample collection and awareness
campaigns), and prevention (post-exposure prophylaxis
costs) amounted to 12 Million Euro [72]. The cost/
effectiveness of the strategy using SAG2 vaccine baits
has been analysed on the basis of the funding allocated by
the European Commission and was demonstrated as more
advantageous than those of neighbouring countries using
different vaccines [72].
5.4 Italy
Italy has been declared rabies-free since 1997. Rabies re-
emerged in Italy in October 2008 in the Friuli-Venezia
Giulia region in north-eastern Italy, near the Slovenian
border [73]. The rabies virus strain isolated was related to
the strains detected in Slovenia, Croatia and other West
Balkan countries [73]. Slovenia had previously successfully
reduced rabies to 2-3 rabies cases/year from 2004 to 2007
after several OV campaigns, but the prevalence of rabiesincreased in Slovenia during 2008 due to increased in-
fection pressure from Croatia, where no OV of foxes
was organized [73]. Nine rabies cases were reported in
Italy during 2008 (Figure 3). Three OV campaigns were
implemented between January and September 2009 in
limited areas in the Friuli Venezia Giulia affected region
using SAG2 baits manually distributed at a density of 20
baits/km2 [74]. Although these manual bait distribution
OV campaigns reduced rabies in the area close to the
Slovenian border, rabies infection spread and reached
the province of Belluno (Veneto Region) during 2009
and the Autonomous Provinces of Trento and Bolzano
between March and August 2010 after the aerial distribu-
tion strategy has been established. Therefore, four emer-
gency vaccination campaigns were conducted according
to the EU recommendations from December 2009 to
December 2010 using aerial distribution by helicopter
in a larger area, including recently affected regions
[75-77]. During December 2009-January 2010, the vacci-
nated area consisted of a 50 km buffer around the location
of the most southerly and most westerly rabid foxes, and
extended to natural or artificial barriers. This campaign
covered 8150 km2 (altitude < 1000 m) and SAD B19 vac-
cine baits were distributed (only SAD B19 vaccine was
available at that time) (Figure 3). Then SAG2 vaccine baits
were used from April 2010 to November 2012, according
to their EU authorization and planned availability. During
April-June 2010, the vaccinated area was extended
westward and covered 27 950 km2 (altitudes < 1500 m,
then < 2300 m due to the perpetuation of rabies foci at
altitudes > 1500 m). Baits were distributed by helicop-
ter at a density of 20-30 baits/km2, with a comple-
mentary hand distribution in urban areas and small
mountain valleys [75-77]. Four ordinary OV cam-
paigns were implemented during spring (May-June)
and autumn (November-December), 2011 and 2012. As
a consequence of vaccination, rabies cases dropped from
207 terrestrial animal rabies cases during 2010 to one fox
case during 2011 (Figure 3), which was detected during
February 2011 in Belluno province. No rabies cases were
reported during 2012. After the detection of the last ra-
bies case during February 2011, an emergency vaccin-
ation near fox dens was implemented in the areas at
higher risk during April 2011 in the Belluno province
(5408 baits were distributed). The country was declared
officially as rabies-free during March 2013. The propor-
tion of foxes with an anti-rabies virus antibody titer
> 0.5 IU/mL ranged according to the vaccination cam-
paign from 46% to 78% [78,79]. The vaccination cam-
paigns planned in 2013 and 2014 were limited to
2385 km2 in the Friuli Venezia Giulia region at the
border from Slovenia. Importantly, all rabies viruses de-
tected in Italy from 2008 to 2011 were analysed and
typed as wild-type strains [80].
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Foxes and raccoon dogs are the main reservoirs of rabies
in Finland. Oral vaccination campaigns began in 1988
[81]. Finland has been declared rabies free since 1991.
To prevent incursions of rabies from Russia, a border
vaccination has been implemented since 1991. Until
April-May 2011, the vaccinated area was limited to
5000 km2 on the south eastern Finish territory along
the Russian border. Since September-October 2011,
due to an expansion of rabies in Russian Karelia and
the occurrence of rabies cases located about 150 km
from Finnish border, the vaccinated area was extended
up to 10 000 km2. SAG2 baits were used from 2010 at
a density of 20 baits/km2. In addition, a cooperation
was established with Russia for vaccination at its bor-
ders with Finland (using a different oral vaccine), with
a financial support from the EU. In the vaccinated area,
no rabies cases were detected in 2011 and 2012. In the
vaccinated area, 53% of wild animals were tetracycline-
positive in 2011 and 66% in 2012 (until October). Neu-
tralizing antibody titers ≥ 0.5 IU/mL were detected in
39% and 55% of wild animals in 2011 and 2012 (six
month follow-up), respectively [81].
6. Conclusions
The success of rabies management through OV of wild-
life populations has been demonstrated in several
European countries. The SAG2 strain provided a safe
and potent alternative to other attenuated strains of ra-
bies virus which retain residual pathogenicity. Use of the
SAG2 vaccine contributed to the elimination of rabies in
Estonia, France, Italy and Switzerland. Importantly, these
countries were declared free of rabies after only few
years of OV campaigns with SAG2 baits (France also
used the recombinant V-RG vaccine) distributed with an
appropriate strategy [29]. The excellent tolerance of the
SAG2 strain has been confirmed in the field since its
first use in 1993. In contrast to other SAD-derived vac-
cines [8,16,82-84], no safety issue have been reported
with SAG2. In particular, no vaccine-induced rabies
cases were documented after the distribution of more
than 20 millions SAG2 baits throughout Europe.
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